MA-HOLOGIC
21.9.2021 13:02:08 CEST | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index , the world’s most comprehensive, globally comparative survey about women’s health.
Developed in partnership with leading analytics and advice firm Gallup, the Hologic Global Women’s Health Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time. Its findings are based on the experiences of more than 60,000 women and girls from 116 countries and territories, captured in more than 140 languages. Conducted as part of the Gallup World Poll, which began in 2005, the Hologic Global Women’s Health Index represents the feelings and actions of approximately 2.5 billion women and girls.
Based on responses from the 120,000 total individuals surveyed, women’s health needs are not being met globally. The global score was 54 out of 100 on the Index, and no one country or territory scored more than 69. Country and territory rankings can be found here . Notably, 40% of those surveyed – equating to about a billion women and girls – said they had not talked to a healthcare professional in the last year, while approximately 60% – about 1.5 billion – were not tested for four common diseases that affect women’s health.
“Women’s health is the cornerstone of families, communities, societies and economies,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “As a leader in the early detection, diagnosis and treatment of women’s health issues, we know firsthand that measurement is the key to improvement. We saw a clear need for more robust, quality data to track and measure women’s health on a global level — particularly as COVID-19 has worsened longstanding healthcare disparities. The Hologic Global Women’s Health Index is the first global survey that uniquely draws from women’s perspectives to determine priorities.”
The Hologic Global Women’s Health Index provides an actionable, science-backed data roadmap for improving life expectancy and quality of life for women and girls worldwide. To help countries and territories determine a strategy for ensuring a healthy future for women, the Index identifies five dimensions of women’s health that explain more than 80% of women’s average life expectancy at birth: Preventive Care, Opinions of Health and Safety, Emotional Health, Individual Health and Basic Needs. In the Index, countries and territories are ranked across each of these five dimensions, then those scores are combined to create an overall ranking. Positive improvements on any of the five dimensions could potentially help women live healthier, longer lives.
“In line with critical UN Sustainable Development Goals and the UN General Assembly theme of ‘Building Resilience Through Hope,’ we urge global healthcare and government leaders to use this data and the five dimensions to guide the development of actionable and measurable plans and investments that prioritize women’s health,” said MacMillan.
While the Hologic Global Women’s Health Index was initiated before COVID-19 affected the world, the pandemic and its effects on the already precarious state of women’s healthcare — including postponed or canceled preventive care examinations, increased poverty levels, and insufficient access to medical facilities and education — have created a more urgent need for world leaders and policymakers to prioritize women’s health.
“The COVID-19 pandemic has both exacerbated and shed light on longstanding gaps in access and quality of healthcare,” said Vipula Gandhi, Senior Managing Partner at Gallup. “The Index provides a baseline from which we can measure the state of women’s health globally. We hope this study will serve as a call to action for world leaders and policymakers as they navigate the global recovery.”
Hologic is committed to conducting the Global Women’s Health Index on a regular basis so world leaders can take action. This commitment builds on Hologic’s more than 30 years of championing women’s health around the world through its products for breast and cervical cancer screening, infectious disease detection, and gynecologic surgery, and its partnerships with numerous global initiatives promoting better access to healthcare .
Country and Territory Rankings Influenced by Disparities in Income and Health Systems
In this first year of the Hologic Global Women’s Health Index, no single country or territory scored more than 69 out of 100. Generally, most countries and territories that lead the world on the Index also lead the world in how much of their wealth they invest back into their health systems, including Austria, Switzerland and Norway. Overall, while women in high-income countries and territories were only 17% of the women surveyed in the Index, they collectively have at least a seven-point lead on the Index over all other women globally.
Conversely, the countries and territories with the lowest scores on the Hologic Global Women’s Health Index all share high income inequality and weak or destabilized infrastructure for healthcare. The countries and territories with the lowest scores on the Index are a mix of mostly low- and lower-middle income economies. Few countries and territories in this group score well in meeting women’s basic needs and are significantly lagging in the Preventive Care dimension.
Universal Challenges Around Preventive Care
“Preventive measures are a crucial first step to combating diseases and infections affecting life expectancy and fertility in women,” said Susan Harvey, MD, Vice-President of Global Medical Affairs, Hologic. “Failing to ensure women get routine testing for cancers, sexually transmitted diseases and infections, and cardiometabolic diseases can lead to larger complications that would otherwise be preventable if monitored or treated early.”
While international testing standards differ, the Hologic Global Women’s Health Index found that within the past 12 months, more than 1.5 billion women were not tested for any of four critical diseases for women: cancer, diabetes, high blood pressure and sexually transmitted diseases/infections (STDs/STIs).
- Just 12% of women worldwide reported being screened for any type of cancer.
- Globally, only about one in five (19%) women reported being screened for diabetes, the sixth leading cause of death for women around the world. In countries and territories with high obesity rates such as the United States, one in three women (34%) reported being tested.
- On average, only one in three women (33%) worldwide had their blood pressure tested despite heart disease being the leading cause of death globally for women and men.
- Fewer than one in nine women (11%) reported being tested for STDs/STIs, which are risk factors for further health issues like HIV, cancer and infertility.
A Holistic Approach to Women’s Health
Collectively, the world in 2020 felt the worst it has in 15 years. Global experiences of worry, stress, sadness and anger continued to rise and set new records. About four in ten women said they experienced worry (40%) and stress (38%) during a lot of the previous day.
Many women surveyed also expressed concerns about their safety and ability to meet basic needs like food and shelter.
- Two in three women (66%) — which translates into roughly 1.7 billion women — cited domestic violence as a widespread problem in their country.
- Nearly one in three (32%) — more than 800 million women — said they are afraid to walk alone at night.
- More than one in three (34%) — nearly 900 million women — said they struggled to afford food in the past year.
- Nearly three in ten (29%) — or nearly 700 million women — said they struggled to afford adequate housing for themselves and their families.
For more information about the Hologic Global Women’s Health Index and year one findings, please visit hologic.womenshealthindex.com .
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .
Hologic and the Global Women’s Health Index are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries and territories.
About the Gallup World Poll
The Gallup World Poll is the most comprehensive and farthest-reaching survey of the world. The survey connects with more than 90% of the world's adult population through annual, nationally representative surveys with comparable metrics across countries and territories. Gallup, Inc. works with organizations across multilaterals, NGOs, private foundations, philanthropies and corporations to measure more than 100 crucial issues affecting people's lives via the World Poll. As a result, the World Poll has become an indispensable tool for global leaders and decision-makers who need to understand the hopes, dreams and behaviors of the people they serve.
Forward Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. There can be no assurance that these efforts will be successful, benefit the Company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.
SOURCE : Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
